ThromboGenics phase 2a trial to evaluate microplasmin in stroke

By Lisa Kerner

Charlotte, N.C., Sept. 22 - ThromboGenics NV began a phase 2a clinical trial at three German sites to evaluate microplasmin for the intra-arterial treatment of stroke in up to 20 patients.

The study, known as Microplasmin MITI-IA (Microplasmin In Treatment of Ischemic Stroke - Intra-Arterial), is the second one started by ThromboGenics to assess the benefits of microplasmin for the treatment of acute ischemic stroke.

Microplasmin, a truncated form of the natural human protein plasmin, is thought to dissolve blood clots and restore blood-flow to the brain after a stroke, according to the Leuven, Belgium, biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.